Clinical Research
Argent Trades Global Rights to Lead Cannabis Drug For Debt Relief in New $5.5m Deal
Argent BioPharma (RGT), formerly MGC Pharmaceuticals, has sold the global commercialisation rights of its leading epilepsy drug, CannEpil, in order to clear a sizable chunk of its debt.